30 closest matches · ranked by relevance
Arteriovenous Malformations
Primary: Target Volume Difference Between Standard of Care vs. CT Angiogram and MRI Alone — 1.1; 1.3 mL
Intracranial Arteriovenous Malformations (AVM)
Primary: Number of Participants With Presence of T2 Weighted Changes on Serial MRI Exam Associated With New Neurological Symptoms — 2 participants
Arteriovenous Malformations
Primary: Number of Participants With Catheter-related Adverse Events at 30 Days — 0 Participants
Hypervascular Tumor and Arteriovenous Malformation
Primary: Success Rate of Embolization in the Target Vessel — 100; 96.4 Percentage of participants
Arteriovenous Fistula · Hemodialysis · Dialysis Adequacy
Primary: Number of Fistula Needle Direction — 72; 92 Participants
Migraine With Aura · Patent Foramen Ovale
Primary: Embolic Tracks
Stenosis · Restenosis
Primary: Number of Participants With Freedom From AV Access Circuit Localized or Systemic Serious Adverse Events — 106 Participants — p=0.0021
End-stage Renal Disease
Primary: Arteriovenous Fistulae Maturation — 50; 40 percentage of group
Cerebrovascular Accident · Moyamoya Disease
Primary: Percentage of Regions With Collateral Versus Antegrade Blood Flow (Sensitivity) Correctly Identified Using MRI With Xenon Contrast Agent (Specificity) — 81.7; 88.9…
Stenosis · Restenosis
Primary: Effectiveness Endpoint: Number of Participants With Target Lesion Primary Patency (TLPP) — 105; 55 Participants — p=<0.001
Vascular Malformations · Vascular Malformation Peripheral · Venous Malformation
Primary: Volume Difference of Malformation to Baseline (no Compression) While Wearing Compression Stockings Class I and II Determined by MRI — 16.38; 23.7 ml
Hereditary Hemorrhagic Telangiectasia
Primary: Change in Lesion Area of Treated Telangiectasia. — -6; -8 mm^2
Arteriovenous Dural Fistula
Primary: Subjects With Neurological Death or Ipsilateral Stroke — 0 Participants
Peripheral Arterial Disease (PAD)
Primary: Segment-level Sensitivity and Specificity of VE-MRI at 3 Ferumoxytol Dosing Levels and Differences in Sensitivity and Specificity by Dose Group — 71.8; 76.8; 81.8; 71.2…
Carotid Atherosclerosis · Peripheral Arterial Disease
Primary: Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth. — -0.47; .07 mm2
Arterio-Venous Fistula · ESRD · Steal Syndrome
Primary: Primary Patency of AVF — 88 Participants
Platelet Aggregation, Spontaneous · Migraine With Aura · Patent Foramen Ovale
Primary: Change in Migraine Characteristics — 43; 2; 17 Participants
Vertebrobasilar Insufficiency · Ischemic Attack, Transient · Cerebrovascular Disorder
Primary: Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory — 72 Participants
Obscure Gastrointestinal Bleeding · Angiodysplasia · Gastric Antral Vascular Ectasia
Primary: Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months — 20; 1 participants — p=0.00000013
Arteriovenous Fistula
Primary: Percentage of Participants With Arteriovenous Fistula (AVF) Maturation by Week 12 Visit Based on Hemodialysis or Color-flow Doppler Ultrasound (CDUS) And Vascular Access…
Abdominal Aortic Aneurysm
Primary: Change in the Growth Rate of Abdominal Aortic Aneurysm — 1.77; 1.81; 1.66 mm — p=0.78
Intracranial Aneurysm
Primary: Prognostic Value of the MAFA (Mean Aneurysm Flow Amplitude) Ratio With Respect to Full Aneurysm Occlusion Within 12 Months — 0.540 probability
Malignant Glioma
Primary: Central Nervous System (CNS) Toxicity — 1 participants
Hemangioma
Primary: MRI/MRA of Head/Neck/Chest. — 357 participants
Chronic Kidney Disease · Chronic Kidney Disease Requiring Chronic Dialysis
Primary: Mean Scores of a Questionnaire Evaluating Patient Confidence in Navigating Vascular Access Care Pre- to Post-program Implementation — 8.0; 8.7 score on a scale — p=0.20
Neovascular Age-Related Macular Degeneration
Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants
Cerebral Hemorrhage · Brain Hemorrhage · Cerebral Parenchymal Hemorrhage
Primary: Global Disability (Functional Outcome) Assessed Via the Ordinal Modified Rankin Score (mRS) — 32; 20; 4; 2 Participants
Intracranial Bifurcating Aneurysms
Primary: Number of Participants With Neurologic Death or Major Ipsilateral Stroke Within 12 Month Follow-up Period. — 5 Participants
CCM · Cavernoma · Cerebral Cavernous Malformation
Primary: Rate of Recurrent Symptomatic Hemorrhage During the Two Year Follow-up Period in Patients With CASH. — 10; 11 Number of new bleeds
AV Fistula
Primary: Time to AV Fistula Functional Maturation — 169; 145 Days to functional maturation